Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Gankyrin is an oncoprotein overexpressed in various cancers, regulating cell proliferation, growth, and migration.
• Gankyrin's interaction with the 26S proteasome is crucial for its oncogenic functions.
• Previous studies explored cjoc42 derivatives to target gankyrin and inhibit cancer cell proliferation.

Purpose of the Study:

• To further enhance the gankyrin binding ability of the cjoc42 scaffold.
• To develop novel cjoc42 derivatives with improved antiproliferative activity against cancer cells.

Main Methods:

• Extensive structure-activity relationship (SAR) studies were conducted on the aryl-triazole moiety of cjoc42.
• Synthesis and evaluation of novel cjoc42 derivatives.
• Assessment of gankyrin binding affinity and antiproliferative activity in various cancer cell lines (Hep3B, HepG2, A549, MDA-MB-231).

Main Results:

• The developed cjoc42 derivatives demonstrated enhanced binding to gankyrin.
• Significant antiproliferative activity was observed for these derivatives against Hep3B, HepG2, A549, and MDA-MB-231 cancer cell lines.
• The SAR studies identified key modifications in the aryl-triazole moiety that contribute to improved efficacy.

Conclusions:

• Novel cjoc42 derivatives exhibit potent gankyrin binding and antiproliferative properties.
• These compounds represent promising candidates for further development as anti-cancer therapeutics targeting gankyrin.
• The findings provide a basis for the rational design of future gankyrin inhibitors.